FDA Labeling Rule Creates Liability Risk For Generics Cos.

Law360, San Diego (November 08, 2013, 10:20 PM ET) -- A new U.S. Food and Drug Administration proposal to let generic-drug manufacturers independently update product labeling when they discover new safety data could open them up to failure-to-warn suits and dilute the effectiveness of their warnings by spurring overdisclosure, lawyers told Law360 Friday.

The rule proposed Friday would remove existing restrictions preventing generic-drug companies from changing safety information until the brand-name counterpart has received agency approval for similar revisions. Generics companies would now be allowed to submit a so-called "changes being effected" supplement, which the FDA...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers